Oculis’ lead molecule enters Phase 3 clinical trials

Oculis’ lead molecule enters Phase 3 clinical trials

15.11.2021 – First patients have been dosed in Oculis’ Phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME). DME is a major complication of diabetes and is a primary cause of vision loss and blindness in people aged 20 and 65.

read more on Oculis news